6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR
申请人:Staben Steven
公开号:US20120214762A1
公开(公告)日:2012-08-23
The invention relates to novel compounds of Formula I:
wherein A, Y, R
1
, R
2
and the subscript b each has the meaning as described herein and compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates, metabolites, isotopes, pharmaceutically acceptable salts, or prodrugs thereof. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.
The present invention provides a novel class of pyridyl-amine fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
The present invention provides a novel class of pyridyl-amine fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
The present invention provides a novel class of pyridyl-amine fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
[EN] PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS<br/>[FR] DÉRIVÉS D'AMINO PYRIDAZINYLE EN TANT QU'INHIBITEURS D'ALK5
申请人:[en]CHIESI FARMACEUTICI S.P.A.
公开号:WO2023046698A1
公开(公告)日:2023-03-30
The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-β (TGF-β) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.